Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

As of Wednesday, December 17, EUDA Health Holdings Limited’s EUDA share price has surged by 5.42%, which has investors ...

These companies could innovate their way to success.

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Shares of gene-editing company Intellia Therapeutics continue to struggle under significant pressure. This follows the U.S. Food and Drug Administration's (FDA) decision to halt the firm's most ...

Intellia Therapeutics finds itself navigating turbulent waters, with its stock price hitting fresh lows as a combination of clinical setbacks and insider sel ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $54.74, moving -2.2% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 1.16%.

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

On Dec. 12, Wood’s Ark funds sold 87,993 shares of Tesla Inc. ( TSLA ), valued at about $40.4 million, marking one of her ...